Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 131 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, sale of pharmaceutical products and provision of license of its intellectual property (IP) or commercialization license. The Company’s main products include targeted therapies, AYVAKIT (avapritinib) and GAVRETO (pralsetinib). The firm is also involved in the development and commercialization of immuno-oncology. The firm mainly conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Follow-Up Questions
Who is the CEO of CStone Pharmaceuticals?
Dr. Jianxin Yang is the Chief Executive Officer of CStone Pharmaceuticals, joining the firm since 2016.
What is the price performance of CSPHF stock?
The current price of CSPHF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for CStone Pharmaceuticals?
CStone Pharmaceuticals belongs to Biotechnology industry and the sector is Health Care
What is CStone Pharmaceuticals market cap?
CStone Pharmaceuticals's current market cap is $0
Is CStone Pharmaceuticals a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for CStone Pharmaceuticals, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
